Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Zaki, 2012, Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia, N Engl J Med, 367, 1814, 10.1056/NEJMoa1211721 Müller, 2015, Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study, Lancet Infect Dis, 15, 559, 10.1016/S1473-3099(15)70090-3 Alraddadi, 2016, Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014, Emerg Infect Dis, 22, 49, 10.3201/eid2201.151340 2018 Aguanno, 2018, MERS: progress on the global response, remaining challenges and the way forward, Antiviral Res, 159, 35, 10.1016/j.antiviral.2018.09.002 Li, 2016, Structure, function, and evolution of coronavirus spike proteins, Annu Rev Virol, 3, 237, 10.1146/annurev-virology-110615-042301 Widagdo, 2019, Host determinants of MERS-CoV transmission and pathogenesis, Viruses, 11, 280, 10.3390/v11030280 Greenberg, 2016, Update on human rhinovirus and coronavirus infections, Semin Respir Crit Care Med, 37, 555, 10.1055/s-0036-1584797 Lu, 2013, Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26, Nature, 500, 227, 10.1038/nature12328 Mou, 2013, The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies, J Virol, 87, 9379, 10.1128/JVI.01277-13 Dicks, 2012, A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity, PLoS One, 7, 10.1371/journal.pone.0040385 Alharbi, 2017, ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice, Vaccine, 35, 3780, 10.1016/j.vaccine.2017.05.032 Munster, 2017, Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model, NPJ Vaccines, 2, 28, 10.1038/s41541-017-0029-1 Alharbi, 2019, Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels, Sci Rep, 9, 10.1038/s41598-019-52730-4 Song, 2013, Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies, J Virol, 87, 11950, 10.1128/JVI.01672-13 Ying, 2015, Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections, Microbes Infect, 17, 142, 10.1016/j.micinf.2014.11.008 Naldini, 1996, Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector, Proc Natl Acad Sci USA, 93, 11382, 10.1073/pnas.93.21.11382 Folegatti, 2019, Safety and immunogenicity of the heterosubtypic influenza A vaccine MVA-NP+M1 manufactured on the AGE1.CR.pIX avian cell line, Vaccines, 7, 33, 10.3390/vaccines7010033 Coughlan, 2018, Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults, EBioMedicine, 29, 146, 10.1016/j.ebiom.2018.02.011 O'Hara, 2012, Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector, J Infect Dis, 205, 772, 10.1093/infdis/jir850 Ewer, 2016, A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA, N Engl J Med, 374, 1635, 10.1056/NEJMoa1411627 Folegatti, 2019, Safety and immunogenicity of a novel recombinant simian adenovirus ChAdOx2 as a vectored vaccine, Vaccines, 7, 40, 10.3390/vaccines7020040 Tseng, 2012, Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus, PLoS One, 7, 10.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a35492 Weingartl, 2004, Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets, J Virol, 78, 12672, 10.1128/JVI.78.22.12672-12676.2004 Liu, 2019, Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection, JCI Insight, 4, 10.1172/jci.insight.123158 Agrawal, 2016, Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus, Hum Vaccin Immunother, 12, 2351, 10.1080/21645515.2016.1177688 van Doremalen, 2020, A single dose of ChAdOx1 MERS provides broad protective immunity against a variety of MERS-CoV strains, bioRxiv Dijkman, 2008, Human coronavirus NL63 and 229E seroconversion in children, J Clin Microbiol, 46, 2368, 10.1128/JCM.00533-08 Widjaja, 2019, Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein, Emerg Microbes Infect, 8, 516, 10.1080/22221751.2019.1597644 Zhao, 2017, Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses, Sci Immunol, 2, 10.1126/sciimmunol.aan5393 Modjarrad, 2019, Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial, Lancet Infect Dis, 19, 1013, 10.1016/S1473-3099(19)30266-X Malczyk, 2015, A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform, J Virol, 89, 11654, 10.1128/JVI.01815-15